How Neurocrine Biosciences Crushed It in Q2
Neurocrine Biosciences' (NASDAQ: NBIX) 30% plunge earlier this year during the coronavirus-fueled market meltdown is practically all but forgotten now. Here's what you need to know about Neurocrine's impressive Q2 update. Neurocrine reported revenue of $302.4 million in the second quarter, a 65% increase from the $183.5 million reported in the prior-year period.